Last updated on July 2019

A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis


Brief description of study

This is a phase 3, randomized, multi-center study that will evaluate upadacitinib versus dupilumab in adults (18-75 years of age) with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy. The study is comprised of a 35-day screening period, a 24-week blinded treatment period, and a 12-week follow-up period.

Clinical Study Identifier: NCT03738397

Find a site near you

Start Over

Ucsd /Id# 208990

San Diego, CA United States
  Connect »

Wake Forest Univ HS /ID# 208892

Winston-Salem, NC United States
  Connect »

Stephen Miller, MD PA /ID# 210071

San Antonio, TX United States
  Connect »

University of Utah /ID# 209001

Salt Lake City, UT United States
  Connect »

Sullivan Dermatology /ID# 208614

North Miami Beach, FL United States
  Connect »

Dawes Fretzin, LLC /ID# 209187

Indianapolis, IN United States
  Connect »

West Virginia Research Inst /ID# 212730

South Charleston, WV United States
  Connect »

Tien Q Nguyen MD, Inc /ID# 208934

Fountain Valley, CA United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.